Women's Heart Health

Penny Anderson Women’s Cardiovascular Center

Join us to advance the understanding of heart and vascular disease in women, how to prevent it and how to optimize patient care.

Now is the time to #ResearchHer.

Heart disease kills more women than all forms of cancer, Alzheimer’s, and respiratory diseases combined. 

When it comes to heart disease, women are under-studied, under-diagnosed, and under-treated. In fact, women’s heart health research is 35 years behind that of men’s heart health research.

Through her extraordinary gift, Penny Anderson is making it possible for MHIF to commit to closing this gap and eliminating the disparities that exist in healthcare delivery and outcomes between men and women by creating the Penny Anderson Women’s Cardiovascular Center. 

Learn more about Penny Anderson’s transformational gift here.

Sign Up For Our Newsletter

Stay up to date on MHIF news, events and the latest information on heart disease treatment and prevention.

First Name
Last Name
CAPTCHA
Sunset

Make a Life-Changing Donation

Any gift, small or large, advances transformative research to save lives.

Give the Gift of Hope
4 photos of families smiling

The Minneapolis Heart Institute Foundation® (MHIF) strives to create a world without heart and vascular disease. To achieve this bold vision, we are dedicated to improving the cardiovascular health of individuals and communities through innovative research and education.

Thanks to the generosity of donors like you, we can continue this life-saving work. Please make a gift to support the area of greatest need.

Research Milestone: FDA approves device used as alternative to open-heart

blue background
Triclip team

We are honored to celebrate the culmination of years of research that has resulted in new technologies for patients! In the few last weeks, we announced a similar research milestone with the FDA approval of the TriClip system for tricuspid regurgitation. We celebrated this important milestone with local media KSTP-TV, who spotlighted the importance of this new technology. We were proud to be a leading clinical site led by Global PI Dr. Paul Sorajja and the MHIF research team who contributed significant data to the pivotal trial.